Legacy Private Trust Co. Has $8.40 Million Stock Position in Eli Lilly and Company $LLY

Key Points

• Legacy Private Trust Co. increased its holdings in Eli Lilly and Company by 5.0%, now owning a total of 10,769 shares valued at approximately $8,395,000.
• Analysts have raised Eli Lilly's rating to a strong-buy, with a current average price target of $941.35 despite some reductions in target prices by other firms.
• Eli Lilly reported a significant quarterly performance, achieving $15.56 billion in revenue, up 37.6% year-over-year, and beat earnings expectations with $6.31 EPS.

Legacy Private Trust Co. increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 5.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,769 shares of the company's stock after buying an additional 512 shares during the quarter. Legacy Private Trust Co.'s holdings in Eli Lilly and Company were worth $8,395,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Duquesne Family Office LLC lifted its holdings in shares of Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock valued at $78,321,000 after purchasing an additional 32,640 shares during the last quarter. Corient IA LLC purchased a new stake in shares of Eli Lilly and Company during the first quarter valued at $570,000. LS Investment Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 1.7% during the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after purchasing an additional 40 shares during the last quarter. Cutter Capital Management LP purchased a new stake in shares of Eli Lilly and Company during the first quarter valued at $14,866,000. Finally, Prism Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the first quarter valued at $207,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 0.9%

LLY stock traded down $7.13 during mid-day trading on Monday, hitting $748.26. The stock had a trading volume of 2,787,993 shares, compared to its average volume of 3,436,359. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $939.86. The company has a fifty day moving average of $740.54 and a 200 day moving average of $774.30. The stock has a market capitalization of $708.20 billion, a price-to-earnings ratio of 48.91, a PEG ratio of 1.05 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the firm posted $3.92 EPS. The business's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Analysts Set New Price Targets

Several brokerages have recently commented on LLY. UBS Group reduced their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reduced their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. Morgan Stanley reaffirmed an "overweight" rating and set a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Daiwa America lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Finally, Daiwa Capital Markets lowered Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $941.35.

Insider Buying and Selling

In related news, CEO David A. Ricks acquired 1,632 shares of the stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 4,514 shares of company stock worth $2,894,841. Insiders own 0.14% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.